Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Core Insights - VolitionRx Limited has announced its first commercial sale of a High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in real time, aiding in the development of new therapeutics for sepsis and related diseases [1][4] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and dedicated to improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring [8][9] Technology and Innovation - The High Throughput NETs model represents a significant breakthrough in understanding neutrophil biology, allowing for more precise measurement of NETs formation in whole blood, which is crucial for therapeutic interventions [2][3] - The innovative approach addresses technical limitations in previous research by measuring NETs directly in whole blood, avoiding alterations in neutrophil responses caused by isolation procedures [3][7] Market Relevance - Sepsis, characterized by a dysregulated host response to infection, results in approximately 370,000 deaths annually in the U.S., highlighting the urgent need for effective diagnostic and therapeutic solutions [4][5] - The understanding of NETs has become increasingly relevant in disease contexts, with overproduction leading to tissue damage and disease progression during inflammatory responses [5][6] Research and Development - Volition is developing cost-effective blood tests aimed at diagnosing and monitoring a range of diseases, including cancers and conditions associated with NETosis, which could significantly improve patient outcomes [6][9]